loading page

HPV prevalence and genotype distribution in Liaocheng men between 2016 and 2022
  • +3
  • Li-li Zheng,
  • Jieyu Qi,
  • Liyuan Zheng,
  • Shuangfeng Chen,
  • Wenhui liu,
  • Ke Li
Li-li Zheng
Liaocheng People's Hospital

Corresponding Author:[email protected]

Author Profile
Jieyu Qi
Liaocheng People's Hospital
Author Profile
Liyuan Zheng
University of Health and Rehabilitation Sciences
Author Profile
Shuangfeng Chen
Liaocheng People's Hospital
Author Profile
Wenhui liu
Liaocheng People's Hospital
Author Profile
Ke Li
Liaocheng People's Hospital
Author Profile

Abstract

HPV infection can lead to HPV-related cancer in men, including the anus, penile, and oropharyngeal cancers and precancerous lesions. This study retrospectively investigated HPV prevalence and genotype distribution in Liaocheng men between 2016 and 2022. The total HPV positive rate was 64.87% (2388/3681, 95% CI: 63.32%-66.40%), where HR-HPV and LR-HPV accounted for 42.49% (1564/3681, 95% CI: 40.90%-44.09%) and 69.71% (2566/3681, 95% CI: 68.20%-71.17%), respectively. The mixed HPV infection rate of two and more genotypes was 35.72%. The infection rate of HR-HPV increased with the number of positive cases annually from 2016 (16.91%) to 2022 (46.59%). The most common HR-HPV genotypes were HPV16 (11.60%), HPV52 (6.95%), and HPV59 (6.28%), whereas the least common HR-HPV was HPV26. The most common LR-HPV genotypes were HPV6 (56.99%), HPV11 (23.79%), and HPV43(6.37%). The 9v HPV vaccine preventable for LR-HPV and HR-HPV accounted for 80.78% and 30.40%, respectively, in this study. Most HPV-positive patients aged 1-86 were in the 30-39 age group. This study confirmed that HPV prevalence in Liaocheng men was common and diverse. HPV16, HPV52, and HPV59 are widely distributed in Liaocheng men, and the male HR-HPV infection rate remained high in this region. Regarding public health and cancer prevention, it is recommended and effective to include the HPV vaccination in the national vaccination program for men.
15 May 2023Submitted to Journal of Medical Virology
19 May 2023Submission Checks Completed
19 May 2023Assigned to Editor
19 May 2023Review(s) Completed, Editorial Evaluation Pending
20 May 2023Reviewer(s) Assigned
13 Jul 2023Editorial Decision: Revise Major
28 Aug 20231st Revision Received
29 Aug 2023Submission Checks Completed
29 Aug 2023Assigned to Editor
29 Aug 2023Review(s) Completed, Editorial Evaluation Pending
15 Oct 2023Reviewer(s) Assigned